"Cancer in children isn’t profitable enough for the pharmaceutical industry"

CRIG
23 November 2020 |

A new method to diagnose cancer more rapidly: pediatric oncologist Bram De Wilde is on the verge of a potential breakthrough with his research. And this despite the pharmaceutical industry: "the patient pool is too small for pharmaceutical companies; they do not invest in it." So, financial backing has to come from somewhere else.

De Wilde is one of many researchers linked to the CRIG, the Cancer Research Institute Ghent. The Ghent research center wants to stimulate and accelerate multidisciplinary cancer research: by sharing knowledge and technology, making collaboration between researchers possible, and by making financial backing available. This is support that primarily comes from donations. As a pediatric oncologist, De Wilde is confronted with the need for donations every day.

Why is there so little money for childhood cancer research?

"Fortunately, cancer is not very prevalent in children: it constitutes only 1% of all types of cancer, but this makes it too small a group for the pharmaceutical industry to invest in; it is not lucrative enough. There is a substantial need for better treatments, as it can have dire consequences for the little patient and their families. We want them to be less subjected to pain during treatment, to suffer less organ damage, and be less impacted by psychological consequences. Things are particularly difficult during that uncertain period when the diagnosis is not yet clear. It is thanks to donations to the CRIG that these unprofitable initiatives can still benefit from financial backing."

What research did you conduct with support from the CRIG?

"We have developed a new technique that defines, with greater certainty, what type of cancer someone has in just a few days’ time and what treatment needs to be followed. Up until today, this usually required a lot more time."

How does this new technique work?

"Instead of taking a tissue sample, the detection of a tumor is done through a blood sample or another liquid biopsy, like urine. The ground-breaking aspect is the speed: within an hour of taking the blood, we can start with the tumor analysis. That is very fast. Another innovation is that we also immediately know exactly what tumor it is. With a tissue biopsy, you are often dealing with metastases and it can be a bit of guesswork to identify the primary tumor. Furthermore, getting a tissue sample is often delicate or even impossible, for instance when it relates to kidneys or the brain. In those instances, we would sometimes have to start treatment without being 100% sure of the diagnosis."

What part did the CRIG play in this?

"Thanks to financial backing from the CRIG, we were able to prove that the test works from a technical standpoint. In other words, we can establish a diagnosis with much more certainty. The first results show that the technique delivers high-quality results. It is important that we now secure the extra funding needed to develop the project further."

Are donations still needed for cancer research today?

"Financing for this type of research by Kom op tegen Kaner or the Fonds voor Wetenschappelijk Onderzoek, for instance, is only awarded if you can show that your project will deliver results. New or early-stage researchers and innovative ideas that don’t yet offer proof will not be considered. Without donations, the research would not have come as far as it has done."

Support CRIG

With CRIG, physicians and researchers from Ghent University, UZ Gent and VIB-UGent are committed to jointly address the medical challenges of the future in cancer treatment. The focus is mainly on top research that, in collaboration with the clinic and the industry, can lead to more effective treatments and to longer and better survival.

Read also

Research into rare eye diseases at Ghent University: “It’s fair to say we rank amongst the world’s elite”

Around 8% of the world’s population suffers from a rare disease. In Belgium some 800,000 patients are affected. One of them is eighteen-month-old Oliver, who was born blind. He is closely monitored by professor Bart Leroy, whose team has made remarkable progress in the research into rare eye diseases. Still, there are quite a few stumbling blocks as well.

Oliver
view

Are vitamin pills innocent?

For many people, a daily dose of vitamins and minerals has become part of their everyday routine. Especially in winter we ingest massive quantities of vitamin D because we think it boosts our immune system. But is that accurate and is that daily vitamin pill as innocent as it appears?

Vitaminen
view

A charitable cause as a birthday gift: Rik and Bea’s inspiring fundraiser

Ghent University alumni Rik and Bea wanted to celebrate their most recent birthday with a big party and they had a very clear gift preference: No flowers or chocolates, they wrote in the invitation, but a donation to the Marleen Temmerman Fund of Ghent University. Their fundraising initiative brought in close to €5,000 for the Fund.

Rik en Bea
view

How to taper off sleeping pills safely and responsibly

In 2023, one in five Belgians was prescribed sleep medication, making Belgium the European leader. “Many people see a sleeping pill as an innocent thing,” says GP and clinical pharmacologist Ellen Van Leeuwen, “but sleeping pills are not sweets.”

Slaapmiddelen
view